Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 14/20 | 0.51 |
| ▸ | CDK1 | P06493 | 12/20 | 0.51 |
| ▸ | CDK4 | P11802 | 12/20 | 0.51 |
| ▸ | CCND1 | P24385 | 12/20 | 0.51 |
| ▸ | CASK | O14936 | 1/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.51 |
| ▸ | CDKL5 | O76039 | 1/20 | 0.51 |
| ▸ | STK10 | O94804 | 1/20 | 0.51 |
| ▸ | CDK14 | O94921 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | MAK | P20794 | 1/20 | 0.51 |
| ▸ | CDK11B | P21127 | 1/20 | 0.51 |
| ▸ | TTK | P33981 | 1/20 | 0.51 |
| ▸ | CLK1 | P49759 | 1/20 | 0.51 |
| ▸ | CLK2 | P49760 | 1/20 | 0.51 |
| ▸ | CLK3 | P49761 | 1/20 | 0.51 |
| ▸ | GSK3A | P49840 | 1/20 | 0.51 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | CDK7 | P50613 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2397064 | 0.88 | CDK1 (0.58) | CDK2CDK1CDK4CCND1CASK | |
| SCHEMBL3837046 | 0.85 | CDK1 (0.51) | CDK2CDK1CDK4CCND1CASK | |
| SCHEMBL3835328 | 0.84 | CDK2 (0.46) | CDK2CDK1CDK4CCND1CASK | |
| SCHEMBL5654700 | 0.84 | CDK1 (0.56) | CDK2CDK1CDK4CCND1CASK | |
| SCHEMBL3835465 | 0.83 | CDK1 (0.43) | CDK2CDK1CDK4CCND1CASK | |
| SCHEMBL3835720 | 0.82 | CDK1 (0.42) | CDK2CDK1CDK4CCND1CASK | |
| SCHEMBL3835671 | 0.82 | CDK1 (0.56) | CDK2CDK1CDK4CCND1SLC6A2 | |
| SCHEMBL3386063 | 0.81 | CDK2 (0.43) | CDK2CDK1CDK4CCND1CASK | |
| SCHEMBL4350445 | 0.81 | CDK1 (0.50) | CDK2CDK1CDK4CCND1CASK | |
| SCHEMBL3837043 | 0.80 | CDK2 (0.40) | CDK2CDK1CDK4CCND1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1771420-B1 | NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-10-14 | — | — | EP | claimed |
| US-7423051-B2 | 2,6-diaminopyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-09 | — | — | US | claimed |
| US-20060014708-A1 | 2,6-Diaminopyridine derivatives | BARTKOVITZ DAVID J | 2006-01-19 | — | — | US | claimed |
| EP-1771420-B1 | NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2009-10-14 | — | — | EP | disclosed |
| US-7423051-B2 | 2,6-diaminopyridine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-09-09 | — | — | US | disclosed |
| EP-1771420-A1 | NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-04-11 | — | — | EP | disclosed |
| US-20060014708-A1 | 2,6-Diaminopyridine derivatives | BARTKOVITZ DAVID J | 2006-01-19 | — | — | US | disclosed |
| WO-2006005548-A1 | NOVEL 2,6-DIAMINOPYRIDINE-3-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014708-A1 | 2,6-Diaminopyridine derivatives | CDK2, CCNA2, CDK6 | CDK2 1/4885CDK1 6/4885CDK4 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.